Skip to main content
Year archive

Zur Rose Group AG — 2021 filings

All 20 regulatory filings released by Zur Rose Group AG (ROSE) in 2021, sourced directly from the official regulator.

20 Filings
2021 Period
2021 filings (20)
Filing Released Lang
Zur Rose Group successfully completed capital increase from authorised capital and sets placement price at CHF 290 per new share
Capital/Financing Update
2021-12-09 English
Zur Rose Group decides on capital increase from authorised capital and starts accelerated bookbuilding to make full use of increasing market opportunities
Capital/Financing Update
2021-12-08 English
Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes
Regulatory Filings
2021-10-28 English
Zur Rose Group: Board of Directors nominates Walter Oberhansli as Chairman and appoints Walter Hess as new CEO
Board/Management Information
2021-10-21 English
Zur Rose Group continues to grow strongly
Earnings Release 9M 2021
2021-10-21 English
Zur Rose Group accelerates growth in second quarter with revenue up 26 per cent
Earnings Release H1 2021
2021-08-18 English
Presentation on half-year results 2021
Investor Presentation H1 2021
2021-08-18 English
Präsentation zum Halbjahresergebnis 2021
Investor Presentation H1 2021
2021-08-18 German
Half-Year Report 2021
Interim / Quarterly Report H2 2021
2021-08-18 English
Halbjahresbericht 2021
Interim / Quarterly Report H2 2021
2021-08-18 German
Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology Officer
Board/Management Information
2021-06-15 English
Annual General Meeting of Zur Rose Group AG: Shareholders approve all proposals
AGM Information
2021-04-29 English
Zur Rose Group signals dynamic revenue development in the first quarter of 2021
Earnings Release Q1 2021
2021-04-20 English
Zur Rose Group AG publishes invitation to the Annual General Meeting on 29 April 2021
AGM Information
2021-04-07 English
Zur Rose Group further extends European market leadership and successfully implements healthcare platform
Earnings Release FY 2020
2021-03-18 English
Präsentation zum Jahresergebnis 2020
Investor Presentation
2021-03-18 German
Presentation on the 2020 annual results
Investor Presentation
2021-03-18 English
The Zur Rose Group accelerates growth
Earnings Release FY 2020
2021-01-21 English
Zur Rose vindicated after court finds CEO Walter Oberhansli not guilty
Legal Proceedings Report
2021-01-13 English
Collaboration between Zur Rose Group and Novo Nordisk: The Zur Rose Group and Novo Nordisk combine their expertise to improve the health journeys of people with obesity
Earnings Release FY 2020
2021-01-11 English